Processa Pharmaceuticals shares surged after the company reported a binding term sheet granting Intact Therapeutics an exclusive option to license a gastroparesis drug candidate but then retreated after Processa announced a $7 million equity offering.
Shares were recently at 30 cents, up 34%, compared with an intraday high of 79 cents.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 17, 2025 12:48 ET (16:48 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.